You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

DURYSTA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


DrugPatentWatch® Litigation and Generic Entry Outlook for Durysta

A generic version of DURYSTA was approved as bimatoprost by APOTEX on December 1st, 2014.

  Try a Trial

Summary for DURYSTA
International Patents:177
US Patents:9
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 74
Patent Applications: 4,457
Drug Prices: Drug price information for DURYSTA
What excipients (inactive ingredients) are in DURYSTA?DURYSTA excipients list
DailyMed Link:DURYSTA at DailyMed
Drug patent expirations by year for DURYSTA
Drug Prices for DURYSTA

See drug prices for DURYSTA

Pharmacology for DURYSTA

US Patents and Regulatory Information for DURYSTA

DURYSTA is protected by nine US patents.

Patents protecting DURYSTA

Hypotensive lipid-containing biodegradable intraocular implants and related implants
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN ANGLE GLAUCOMA(OAG) OR OCULAR HYPERTENSION (OHT) WITH A BIODEGRADABLE BIMATOPROST IMPLANT

Processes for making cyclic lipid implants for intraocular use
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Hypotensive lipid-containing biodegradable intraocular implants and related methods
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Hypotensive lipid-containing biodegradable intraocular implants and related methods
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN ANGLE GLAUCOMA(OAG) OR OCULAR HYPERTENSION (OHT) WITH A BIODEGRADABLE BIMATOPROST IMPLANT

7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-N-ethyl-hept-5-enamide (bimatoprost) in crystalline form II, methods for preparation, and methods for use thereof
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Intraocular pressure reduction with intracameral bimatoprost implants
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN ANGLE GLAUCOMA(OAG) OR OCULAR HYPERTENSION (OHT) WITH A BIODEGRADABLE BIMATOPROST IMPLANT

Processes for making cyclic lipid implants for intraocular use
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Prostamide-containing intraocular implants and methods of use thereof
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Prostamide-containing intraocular implants and methods of use thereof
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN ANGLE GLAUCOMA(OAG) OR OCULAR HYPERTENSION (OHT) WITH A BIODEGRADABLE BIMATOPROST IMPLANT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie DURYSTA bimatoprost IMPLANT;OPHTHALMIC 211911-001 Mar 4, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Abbvie DURYSTA bimatoprost IMPLANT;OPHTHALMIC 211911-001 Mar 4, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Abbvie DURYSTA bimatoprost IMPLANT;OPHTHALMIC 211911-001 Mar 4, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Abbvie DURYSTA bimatoprost IMPLANT;OPHTHALMIC 211911-001 Mar 4, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Abbvie DURYSTA bimatoprost IMPLANT;OPHTHALMIC 211911-001 Mar 4, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for DURYSTA

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
AbbVie Deutschland GmbH & Co. KG Lumigan bimatoprost EMEA/H/C/000391
Reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension (as monotherapy or as adjunctive therapy to beta-blockers).,
Authorised no no no 2002-03-08
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for DURYSTA

See the table below for patents covering DURYSTA around the world.

Country Patent Number Title Estimated Expiration
Brazil 112012012387 7-[3,5-di-hidroxi-5-fenil-pent-1-enil)-ciclopentil]-n-etil-hept-5-enamida (bimatoprost) na forma cristalina ii, métodos para a preparação e métodos de utilização da mesma ⤷  Try a Trial
Colombia 6551754 7-[3.5-DIHIDROXI-2-(3-HIDRIXI-5-FENIL-PENT-1-ENIL)- CICLOPENTIL] -N-ETIL-HEPT-5-ENAMIDA(BIMATOPROST) EN FORMA CRISTALINA II, MÈTODOS PARA LA PREPARACIÒN Y MÈTODO PARA SU USO ⤷  Try a Trial
China 104288155 Biodegradable intraocular implants containing prostamides ⤷  Try a Trial
Singapore 10201606415U Intraocular Pressure Reduction With Intracameral Bimatoprost Implants ⤷  Try a Trial
Japan 6482547 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for DURYSTA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0660716 C300099 Netherlands ⤷  Try a Trial PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION: EU/1/02/205/001 20020308
0660716 02C0033 France ⤷  Try a Trial PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION:
0660716 SPC/GB02/035 United Kingdom ⤷  Try a Trial PRODUCT NAME: BIMATOPROST; REGISTERED: UK EU/1/02/205/001 20020308
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.